B. Riley raised the firm’s price target on Tango Therapeutics (TNGX) to $14 from $8 and keeps a Buy rating on the shares. Tango’s enterprise valuation expansion from $200M to $800M suggests the market values vopimetostat’s safety differentiation, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNGX:
- Tango Therapeutics initiated with a Peer Perform at Wolfe Research
- Tango Therapeutics Reports Promising Q3 2025 Results
- Tango Therapeutics reports Q3 EPS 14c, consensus (7c)
- Tango Therapeutics, Inc. (TNGX) Q3 Earnings Cheat Sheet
- Tango Therapeutics Advances Innovative Cancer Treatment with S095035 Clinical Trial